MANNKIND CORP Operating Lease, Right-of-Use Asset, Amortization Expense
MANNKIND CORP (MNKD) reported Operating Lease, Right-of-Use Asset, Amortization Expense of $976.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Operating Activities
us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense · last filed 2026-08-05
- MANNKIND CORP operating lease, right-of-use asset, amortization expense for the quarter ending 2026-06-30 was $444.00K, a 16.38% decline year-over-year.
- MANNKIND CORP operating lease, right-of-use asset, amortization expense for the quarter ending 2026-03-31 was $532.00K, a 2.21% decline year-over-year.
- MANNKIND CORP operating lease, right-of-use asset, amortization expense for the quarter ending 2025-12-31 was -$603.00K, a 214.20% decline year-over-year.
- MANNKIND CORP operating lease, right-of-use asset, amortization expense for the quarter ending 2025-09-30 was $740.00K, a 50.10% increase year-over-year.
- MANNKIND CORP operating lease, right-of-use asset, amortization expense for fiscal 2025 was $1.21M, a 27.34% decline from fiscal 2024.
- MANNKIND CORP operating lease, right-of-use asset, amortization expense for fiscal 2024 was $1.67M, a 28.21% increase from fiscal 2023.
- MANNKIND CORP operating lease, right-of-use asset, amortization expense for fiscal 2023 was $1.30M, a 56.44% decline from fiscal 2022.
- MANNKIND CORP operating lease, right-of-use asset, amortization expense for fiscal 2022 was $2.99M, a 137.44% increase from fiscal 2021.
| Period end | Operating Lease, Right-of-Use Asset, Amortization Expense 3 month | Operating Lease, Right-of-Use Asset, Amortization Expense 6 month | Operating Lease, Right-of-Use Asset, Amortization Expense 9 month | Operating Lease, Right-of-Use Asset, Amortization Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $444.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $976.00K 10-Q · filed 2026-08-05 | $373.00K derived: sum of 3 quarters · filed 2026-08-05 | $1.11M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $532.00K 10-Q · filed 2026-05-06 | -$71.00K derived: sum of 2 quarters · filed 2026-05-06 | $669.00K derived: sum of 3 quarters · filed 2026-05-06 | $1.20M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | -$603.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $137.00K derived: sum of 2 quarters · filed 2026-02-26 | $668.00K derived: sum of 3 quarters · filed 2026-08-05 | $1.21M 10-K · filed 2026-02-26 |
| 2025-09-30 | $740.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $1.27M derived: sum of 2 quarters · filed 2026-08-05 | $1.81M 10-Q · filed 2025-11-05 | $2.34M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $531.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $1.07M 10-Q · filed 2026-08-05 | $1.60M derived: sum of 3 quarters · filed 2026-08-05 | $2.10M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $544.00K 10-Q · filed 2026-05-06 | $1.07M derived: sum of 2 quarters · filed 2026-05-06 | $1.56M derived: sum of 3 quarters · filed 2026-05-06 | $1.88M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $528.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $1.02M derived: sum of 2 quarters · filed 2026-02-26 | $1.34M derived: sum of 3 quarters · filed 2026-02-26 | $1.67M 10-K · filed 2026-02-26 |
| 2024-09-30 | $493.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $812.00K derived: sum of 2 quarters · filed 2025-11-05 | $1.14M 10-Q · filed 2025-11-05 | $1.46M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $319.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | $647.00K 10-Q · filed 2025-08-06 | $970.00K derived: sum of 3 quarters · filed 2026-02-26 | $1.29M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $328.00K 10-Q · filed 2025-05-08 | $651.00K derived: sum of 2 quarters · filed 2026-02-26 | $972.00K derived: sum of 3 quarters · filed 2026-02-26 | $1.29M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $323.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $644.00K derived: sum of 2 quarters · filed 2026-02-26 | $963.00K derived: sum of 3 quarters · filed 2026-02-26 | $1.30M 10-K · filed 2026-02-26 |
| 2023-09-30 | $321.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $640.00K derived: sum of 2 quarters · filed 2024-11-07 | $978.00K 10-Q · filed 2024-11-07 | $1.31M derived: sum of 4 quarters · filed 2025-02-26 |
| 2023-06-30 | $319.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07 | $657.00K 10-Q · filed 2024-08-07 | $989.00K derived: sum of 3 quarters · filed 2025-02-26 | $1.31M derived: sum of 4 quarters · filed 2025-02-26 |
| 2023-03-31 | $338.00K 10-Q · filed 2024-05-08 | $670.00K derived: sum of 2 quarters · filed 2025-02-26 | $994.00K derived: sum of 3 quarters · filed 2025-02-26 | $3.04M derived: sum of 4 quarters · filed 2025-02-26 |
| 2022-12-31 | $332.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-26 | $656.00K derived: sum of 2 quarters · filed 2025-02-26 | $2.70M derived: sum of 3 quarters · filed 2025-02-26 | $2.99M 10-K · filed 2025-02-26 |
| 2022-09-30 | $324.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $2.37M derived: sum of 2 quarters · filed 2023-11-07 | $2.65M 10-Q · filed 2023-11-07 | $3.41M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-06-30 | $2.04M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-07 | $2.33M 10-Q · filed 2023-08-07 | $3.08M derived: sum of 3 quarters · filed 2024-02-27 | $2.92M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-03-31 | $289.00K 10-Q · filed 2023-05-09 | $1.04M derived: sum of 2 quarters · filed 2024-02-27 | $879.00K derived: sum of 3 quarters · filed 2024-02-27 | $1.24M derived: sum of 4 quarters · filed 2024-02-27 |
| 2021-12-31 | $753.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $590.00K derived: sum of 2 quarters · filed 2024-02-27 | $949.00K derived: sum of 3 quarters · filed 2024-02-27 | $1.26M 10-K · filed 2024-02-27 |
| 2021-09-30 | -$163.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $196.00K derived: sum of 2 quarters · filed 2022-11-08 | $505.00K 10-Q · filed 2022-11-08 | $803.00K derived: sum of 4 quarters · filed 2023-02-23 |
| 2021-06-30 | $359.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $668.00K 10-Q · filed 2022-08-09 | $966.00K derived: sum of 3 quarters · filed 2023-02-23 | $1.27M derived: sum of 4 quarters · filed 2023-02-23 |
| 2021-03-31 | $309.00K 10-Q · filed 2022-05-05 | $607.00K derived: sum of 2 quarters · filed 2023-02-23 | $910.00K derived: sum of 3 quarters · filed 2023-02-23 | $1.20M derived: sum of 4 quarters · filed 2023-02-23 |
| 2020-12-31 | $298.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | $601.00K derived: sum of 2 quarters · filed 2023-02-23 | $895.00K derived: sum of 3 quarters · filed 2023-02-23 | $1.18M 10-K · filed 2023-02-23 |
| 2020-09-30 | $303.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09 | $597.00K derived: sum of 2 quarters · filed 2021-11-09 | $879.00K 10-Q · filed 2021-11-09 | |
| 2020-06-30 | $294.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-11 | $576.00K 10-Q · filed 2021-08-11 | ||
| 2020-03-31 | $282.00K 10-Q · filed 2021-05-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 |